



US 20250255954A1

(19) **United States**

(12) **Patent Application Publication**

Wu et al.

(10) **Pub. No.: US 2025/0255954 A1**

(43) **Pub. Date: Aug. 14, 2025**

(54) **STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE**

(71) Applicants: **Yuanhan Wu**, Philadelphia, PA (US); **Susanne Walker**, Wilmington, DE (US); **Daniel Kulp**, Moorestown, NJ (US); **The Wistar Institute of Anatomy and Biology**, Philadelphia, PA (US)

(72) Inventors: **Yuanhan Wu**, Philadelphia, PA (US); **Susanne Walker**, Wilmington, DE (US); **Daniel Kulp**, Moorestown, NJ (US)

(21) Appl. No.: **18/856,345**

(22) PCT Filed: **Apr. 11, 2023**

(86) PCT No.: **PCT/US2023/065623**

§ 371 (c)(1),

(2) Date: **Oct. 11, 2024**

Related U.S. Application Data

(60) Provisional application No. 63/329,687, filed on Apr. 11, 2022.

Publication Classification

(51) **Int. Cl.**

A61K 39/215 (2006.01)

C07K 14/005 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 39/215** (2013.01); **C07K 14/005** (2013.01); **C12N 2770/20022** (2013.01); **C12N 2770/20034** (2013.01)


(57)

ABSTRACT

Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.

Specification includes a Sequence Listing.

A



3 RBDs Down




RBD 1 Up



RBD 2 Up



3 RBDs Up



A

Fig. 1A




Fig. 1B





Fig. 1C



E




Fig. 1E




Fig. 1F





Fig. 1G



**STABILIZED SPIKE PROTEIN AND
METHOD OF USE THEREOF AS A
CORONAVIRUS DISEASE 2019 (COVID-19)
VACCINE**

**CROSS REFERENCE TO RELATED
APPLICATIONS**

[0001] This application claims priority to U.S. Provisional Application No. 63/329,687, filed Apr. 11, 2022, which is hereby incorporated by reference herein in its entirety.

BACKGROUND

[0002] Since late 2019, an outbreak of coronavirus disease has caused significant death tolls and economic damage to the world. By Apr. 1, 2022, there are over 486 million COVID-19 cases and 6.14 million deaths resulting from it (WHO COVID-19 Dashboard, [hBps://covid19.who.int](https://covid19.who.int)). The causal agent of the pandemic is a novel beta coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). To date, multiple vaccines had been developed to counter the pathogen (Smith et al., 2020, Nature communications 11.1:1-13) with many others in clinical trials. Most of the current vaccine approaches utilize the Spike(S) glycoprotein, which mediates receptor recognition and host cell entry, as an immunogen. Structural studies of the S proteins from previous coronaviruses revealed that the RBD is highly flexible and displays dynamic configurations among the more exposed up states and the more buried down states (Yuan et al., 2017, Nature communications 8.1:1-9; Pallesen et al., 2017,

[0003] Proceedings of the National Academy of Sciences 114.35: E7348-E7357). Similar types of RBD dynamics in the S protein was also confirmed in SARSCOV-2. Structures of the ACE2 receptor bound to the RBD in the up conformation suggested that the RBD up state may be more relevant to host cell receptor binding and prone to neutralization by the immune system.

[0004] Accordingly, a need remains in the art for the development of a safe and effective vaccine for the treatment of SARS-COV-2 infection or the treatment or prevention of a disease or disorder associated with SARS-COV-2 infection such as COVID-19.

SUMMARY OF THE INVENTION

[0005] In one embodiment, the invention relates to a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4.

[0006] In one embodiment, the invention relates to a composition comprising a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0007] In one embodiment, the invention relates to a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodi-

ment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the nucleic acid molecule is incorporated into a nanoparticle.

[0008] In one embodiment, the invention relates to a nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule.

[0009] In one embodiment, the invention relates to an immunogenic composition comprising at least one nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0010] In one embodiment, the invention relates to an immunogenic composition comprising at least one nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0011] In one embodiment, the invention relates to a method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4.

[0012] In one embodiment, the invention relates to a method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering an immunogenic composition comprising a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the immunogenic composition further comprises a pharmaceutically accept-

able excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0013] In one embodiment, the invention relates to a method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the nucleic acid molecule is incorporated into a nanoparticle.

[0014] In one embodiment, the invention relates to a method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering a nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule.

[0015] In one embodiment, the invention relates to a method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering an immunogenic composition comprising at least one nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0016] In one embodiment, the invention relates to a method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering an immunogenic composition comprising at least one nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0017] In one embodiment, the invention relates to a method of protecting a subject in need thereof from infection with SARS-COV-2, the method comprising administering a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4 to the subject, wherein the subject is thereby

resistant to one or more SARS-COV-2 strains. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4.

[0018] In one embodiment, the invention relates to a method of protecting a subject in need thereof from infection with SARS-COV-2, the method comprising administering an immunogenic composition comprising a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4 to the subject, wherein the subject is thereby resistant to one or more SARS-COV-2 strains. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0019] In one embodiment, the invention relates to a method of protecting a subject in need thereof from infection with SARS-COV-2, the method comprising administering a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4 to the subject, wherein the subject is thereby resistant to one or more SARS-COV-2 strains. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the nucleic acid molecule is incorporated into a nanoparticle.

[0020] In one embodiment, the invention relates to a method of protecting a subject in need thereof from infection with SARS-COV-2, the method comprising administering a nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4 to the subject, wherein the subject is thereby resistant to one or more SARS-COV-2 strains. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule.

[0021] In one embodiment, the invention relates to a method of protecting a subject in need thereof from infection with SARS-COV-2, the method comprising administering an immunogenic composition comprising at least one nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4 to the subject, wherein the subject is thereby resistant to one or more SARS-COV-2 strains. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0022] In one embodiment, the invention relates to a method of protecting a subject in need thereof from infection

with SARS-COV-2, the method comprising administering an immunogenic composition comprising at least one nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4 to the subject, wherein the subject is thereby resistant to one or more SARS-COV-2 strains. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0023] In one embodiment, the invention relates to a method of treating a subject in need thereof against SARS-COV-2, the method comprising administering a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4.

[0024] In one embodiment, the invention relates to a method of treating a subject in need thereof against SARS-COV-2, the method comprising administering an immunogenic composition comprising a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0025] In one embodiment, the invention relates to a method of treating a subject in need thereof against SARS-COV-2, the method comprising administering a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the nucleic acid molecule is incorporated into a nanoparticle.

[0026] In one embodiment, the invention relates to a method of treating a subject in need thereof against SARS-COV-2, the method comprising administering a nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule.

[0027] In one embodiment, the invention relates to a method of treating a subject in need thereof against SARS-COV-2, the method comprising administering an immunogenic composition comprising at least one nucleic acid

molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3. In one embodiment, the nucleic acid molecule comprises an expression vector. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

[0028] In one embodiment, the invention relates to a method of treating a subject in need thereof against SARS-COV-2, the method comprising administering an immunogenic composition comprising at least one nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen comprising SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the stabilized spike antigen is operably linked to a leader sequence. In one embodiment, the stabilized spike antigen comprises a sequence as set forth in SEQ ID NO:4. In one embodiment, the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule. In one embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient. In one embodiment, the immunogenic composition further comprises an adjuvant.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] FIG. 1A through FIG. 1H depict data demonstrating the forced up conformation of SARS-COV-2 RBD structure-based design. FIG. 1A: Structural model of 6P with RBDs in each of the four up/down conformation combinations. (PDB:6VSB) FIG. 1B: Density plot of inter-residue distances between an up or down state. Black box indicates the selected residues with a small down distance and a large up distance. FIG. 1C: Heat map displaying the clusters of residues in close proximity with a large delta distance (left) and the clusters mapped onto an RBD structure (right). FIG. 1D: Delta Fa_rep scores for mutational variants on clusters 1, 2 and 3. A negative score indicates a favored up state and positive values indicate a favored down state. FIG. 1E: Histogram of sugar scores calculated from native glycoproteins shows where the majority of glycans score compared to the two novel down-selected glycan candidates. FIG. 1F: Cryo-EM structure composed from class averages which validate an all up conformation 100% of structures. FIG. 1G: Pseudoneutralization ID50 titers for mice immunized with 6P or the UpGly protein with RIBI adjuvant for all relevant variants of concern. FIG. 1H: A model of the RBD neutralizing epitopes (left) and antigenic profile defined by large epitopes in a competition ELISA and refined epitopes in a glycan blocking ELISA.

DETAILED DESCRIPTION OF THE INVENTION

[0030] The present invention relates to the development of a stabilized spike antigen with a stabilized prefusion spike which forces a 100% all up conformation for RBDs and methods of use thereof as a vaccine for SARS-COV-2 infection or a disease or disorder associated therewith. In

some embodiments, the disease or disorder associated with SARS-COV-2 infection is COVID-19.

1. Definitions

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

[0032] The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.

[0033] “Adjuvant” as used herein means any molecule added to the vaccine described herein to enhance the immunogenicity of the antigen.

[0034] “Antibody” as used herein means an antibody of classes IgG, IgM, IgA, IgD or IgE, or fragments, fragments or derivatives thereof, including Fab, F(ab')₂, Fd, and single chain antibodies, diabodies, bispecific antibodies, bifunctional antibodies and derivatives thereof. The antibody can be an antibody isolated from the serum sample of mammal, a polyclonal antibody, affinity purified antibody, or mixtures thereof which exhibits sufficient binding specificity to a desired epitope or a sequence derived therefrom.

[0035] “Coding sequence” or “encoding nucleic acid” as used herein means the nucleic acids (RNA or DNA molecule) that comprise a nucleotide sequence which encodes a protein. The coding sequence can further include initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered.

[0036] “Complement” or “complementary” as used herein means Watson-Crick (e.g., A-T/U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules.

[0037] “Consensus” or “Consensus Sequence” as used herein may mean a synthetic nucleic acid sequence, or corresponding polypeptide sequence, constructed based on analysis of an alignment of multiple subtypes of a particular antigen. The sequence may be used to induce broad immunity against multiple subtypes, serotypes, or strains of a particular antigen. Synthetic antigens, such as fusion proteins, may be manipulated to generate consensus sequences (or consensus antigens).

[0038] “Electroporation,” “electro-permeabilization,” or “electro-kinetic enhancement” (“EP”) as used interchangeably herein means the use of a transmembrane electric field pulse to induce microscopic pathways (pores) in a biomembrane; their presence allows biomolecules such as

plasmids, oligonucleotides, siRNA, drugs, ions, and water to pass from one side of the cellular membrane to the other.

[0039] “Fragment” as used herein means a nucleic acid sequence or a portion thereof that encodes a polypeptide capable of eliciting an immune response in a mammal. The fragments can be DNA fragments selected from at least one of the various nucleotide sequences that encode protein fragments set forth below.

[0040] “Fragment” or “immunogenic fragment” with respect to polypeptide sequences means a polypeptide capable of eliciting an immune response in a mammal that cross reacts with a full length wild type strain SARS-COV-2 antigen. Fragments of consensus proteins can comprise at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of a consensus protein. In some embodiments, fragments of consensus proteins can comprise at least 20 amino acids or more, at least 30 amino acids or more, at least 40 amino acids or more, at least 50 amino acids or more, at least 60 amino acids or more, at least 70 amino acids or more, at least 80 amino acids or more, at least 90 amino acids or more, at least 100 amino acids or more, at least 110 amino acids or more, at least 120 amino acids or more, at least 130 amino acids or more, at least 140 amino acids or more, at least 150 amino acids or more, at least 160 amino acids or more, at least 170 amino acids or more, at least 180 amino acids or more, at least 190 amino acids or more, at least 200 amino acids or more, at least 210 amino acids or more, at least 220 amino acids or more, at least 230 amino acids or more, or at least 240 amino acids or more of a consensus protein.

[0041] As used herein, the term “genetic construct” refers to the DNA or RNA molecules that comprise a nucleotide sequence which encodes a protein. The coding sequence includes initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of the individual to whom the nucleic acid molecule is administered. As used herein, the term “expressible form” refers to gene constructs that contain the necessary regulatory elements operably linked to a coding sequence that encodes a protein such that when present in the cell of the individual, the coding sequence will be expressed.

[0042] “Identical” or “identity” as used herein in the context of two or more nucleic acids or polypeptide sequences, means that the sequences have a specified percentage of residues that are the same over a specified region. The percentage can be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent. Identity can be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0.

[0043] “Immune response” as used herein means the activation of a host’s immune system, e.g., that of a mammal, in response to the introduction of antigen. The immune response can be in the form of a cellular or humoral response, or both.

[0044] “Nucleic acid” or “oligonucleotide” or “polynucleotide” as used herein means at least two nucleotides covalently linked together. The depiction of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid also encompasses the complementary strand of a depicted single strand. Many variants of a nucleic acid can be used for the same purpose as a given nucleic acid. Thus, a nucleic acid also encompasses substantially identical nucleic acids and complements thereof. A single strand provides a probe that can hybridize to a target sequence under stringent hybridization conditions. Thus, a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions.

[0045] Nucleic acids can be single stranded or double stranded, or can contain portions of both double stranded and single stranded sequence. The nucleic acid can be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid can contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids can be obtained by chemical synthesis methods or by recombinant methods.

[0046] “Operably linked” as used herein means that expression of a gene is under the control of a promoter with which it is spatially connected. A promoter can be positioned 5’ (upstream) or 3’ (downstream) of a gene under its control. The distance between the promoter and a gene can be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance can be accommodated without loss of promoter function.

[0047] A “peptide,” “protein,” or “polypeptide” as used herein can mean a linked sequence of amino acids and can be natural, synthetic, or a modification or combination of natural and synthetic.

[0048] “Promoter” as used herein means a synthetic or naturally-derived molecule which is capable of conferring, activating or enhancing expression of a nucleic acid in a cell. A promoter can comprise one or more specific transcriptional regulatory sequences to further enhance expression and/or to alter the spatial expression and/or temporal expression of same. A promoter can also comprise distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A promoter can be derived from sources including viral, bacterial, fungal, plants, insects, and animals. A promoter can regulate the expression of a gene component constitutively or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents. Representative examples of promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early

promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter and the CMV IE promoter.

[0049] “Signal peptide” and “leader sequence” are used interchangeably herein and refer to an amino acid sequence that can be linked at the amino terminus of a SARS-CoV-2 protein set forth herein. Signal peptides/leader sequences typically direct localization of a protein. Signal peptides/leader sequences used herein preferably facilitate secretion of the protein from the cell in which it is produced. Signal peptides/leader sequences are often cleaved from the remainder of the protein, often referred to as the mature protein, upon secretion from the cell. Signal peptides/leader sequences are linked at the N terminus of the protein.

[0050] “Subject” as used herein can mean a mammal that wants to or is in need of being immunized with the herein described vaccine. The mammal can be a human, chimpanzee, dog, cat, horse, cow, mouse, or rat.

[0051] “Substantially identical” as used herein can mean that a first and second amino acid sequence are at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 or more amino acids. Substantially identical can also mean that a first nucleic acid sequence and a second nucleic acid sequence are at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 or more nucleotides.

[0052] “Treatment” or “treating,” as used herein can mean protecting of an animal from a disease through means of preventing, suppressing, repressing, or completely eliminating the disease. Preventing the disease involves administering a vaccine of the present invention to an animal prior to onset of the disease. Suppressing the disease involves administering a vaccine of the present invention to an animal after induction of the disease but before its clinical appearance. Repressing the disease involves administering a vaccine of the present invention to an animal after clinical appearance of the disease.

[0053] “Variant” used herein with respect to a nucleic acid means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or the complement thereof; or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, complement thereof, or a sequences substantially identical thereto.

[0054] Variant can further be defined as a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Representative examples of “biological activity” include the ability to be bound by a specific antibody or to promote an immune response. Variant can also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one

biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., *J. Mol. Biol.* 157:105-132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of ± 2 are substituted. The hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions can be performed with amino acids having hydrophilicity values within ± 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.

[0055] A variant may be a nucleic acid sequence that is substantially identical over the full length of the full gene sequence or a fragment thereof. The nucleic acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof. A variant may be an amino acid sequence that is substantially identical over the full length of the amino acid sequence or fragment thereof. The amino acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the amino acid sequence or a fragment thereof.

[0056] "Vector" as used herein means a nucleic acid sequence containing an origin of replication. A vector can be a viral vector, bacteriophage, bacterial artificial chromosome or yeast artificial chromosome. A vector can be a DNA or RNA vector. A vector can be a self-replicating extrachromosomal vector, and preferably, is a DNA plasmid.

[0057] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

2. Conformational Shifting by Distance and Volume Analysis

[0058] In some embodiments, the invention provides a general method that can be used for changing dynamics of viral glycoproteins. Disclosed herein is a new method

referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. In some embodiments, the method includes generating a density plot of inter-residue distances between an up or down state, generating a heat map displaying the clusters of residues in close proximity with a large delta distance, mapping the onto a protein structure, and generating Delta Fa_rep scores for mutational variants on the clusters, wherein a negative score indicates a favored up state and positive values indicate a favored down state.

[0059] In one embodiment, the method of the invention is used to identify sites that can be modified by adding a glycan to alter the conformation of a protein or domain.

3. Stabilized Spike antigen

[0060] Coronaviruses, including SARS-COV-2, are encapsulated by a membrane and have a type 1 membrane glycoprotein known as spike(S) protein, which forms protruding spikes on the surface of the coronavirus. The spike protein facilitates binding of the coronavirus to proteins located on the surface of a cell, for example, the metallo-protease amino peptidase N, and mediates cell-viral membrane fusion. In particular, the spike protein contains an S1 subunit that facilitates binding of the coronavirus to cell surface proteins and thus comprises a receptor binding domain (RBD). Accordingly, the S1 subunit of the spike protein controls which cells are infected by the coronavirus.

[0061] The invention is based in part on the development of stabilized spike protein and nucleic acid molecules encoding the same, wherein the stabilized spike immunogen forces the 6 RBD into up conformations. In one embodiment, the invention relates to a vaccine comprising a stabilized spike protein, a fragment thereof, a variant thereof, or a combination thereof.

[0062] In one embodiment, the composition of the invention is capable of eliciting an immune response in a mammal against one or more SARS-COV-2 strains. The SARS-COV-2 antigen can comprise an epitope(s) that makes it particularly effective as an immunogen against which an anti-SARS-COV-2 immune response can be induced.

[0063] The stabilized spike antigen can comprise a consensus sequence and/or modification(s) for improved expression. Modification can include codon optimization, RNA optimization, addition of a kozak sequence for increased translation initiation, and/or the addition of an immunoglobulin leader sequence to increase the immunogenicity of the stabilized spike antigen. The stabilized spike antigen can comprise a signal peptide such as an immunoglobulin signal peptide, for example, but not limited to, an immunoglobulin E (IgE) or immunoglobulin (IgG) signal peptide. In one embodiment, the stabilized spike antigen can have an amino acid sequence of SEQ ID NO:4 which includes an IgE leader sequence.

[0064] The stabilized spike antigen can have an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. In some embodiments, the SARS-COV-2 stabilized spike antigen can be an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4.

[0065] The nucleic acid molecule encoding the stabilized spike antigen can comprise the nucleic acid sequence of SEQ ID NO:1, which encodes SEQ ID NO:2. The nucleic

acid molecule encoding the stabilized spike antigen can comprise the nucleic acid sequence of SEQ ID NO:3, which encodes SEQ ID NO:4. In some embodiments, the nucleic acid molecule encoding the stabilized spike antigen can comprise a nucleotide sequence that encodes the amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:4. In some embodiments, the nucleic acid molecule encoding the stabilized spike antigen can comprise a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity over an entire length of the nucleic acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:3. In some embodiments, the stabilized spike antigen can be operably linked to an IgE leader sequence. In some embodiments, the stabilized spike antigen operably linked to an IgE leader sequence comprises SEQ ID NO:3.

[0066] Immunogenic fragments of SEQ ID NO:2 or SEQ ID NO:4 can be provided. Immunogenic fragments can comprise at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of SEQ ID NO:2 or SEQ ID NO:4. In some embodiments, immunogenic fragments include a leader sequence, such as for example an immunoglobulin leader, such as the IgE leader. In some embodiments, immunogenic fragments are free of a leader sequence.

[0067] Immunogenic fragments of proteins with amino acid sequences homologous to immunogenic fragments of SEQ ID NO:2 or SEQ ID NO:4 can be provided. Such immunogenic fragments can comprise at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO:2 or SEQ ID NO:4. In some embodiments, immunogenic fragments include a leader sequence, such as for example an immunoglobulin leader, such as the IgE leader. In some embodiments, immunogenic fragments are free of a leader sequence.

[0068] Some embodiments relate to immunogenic fragments of SEQ ID NO:1 or SEQ ID NO:3. Immunogenic fragments can be at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of the full length of SEQ ID NO:1 or SEQ ID NO:3. Immunogenic fragments can comprise at least 95%, at least 96%, at least 97% at least 98% or at least 99% identity to fragments of SEQ ID NO:1 or SEQ ID NO:3. In some embodiments, immunogenic fragments include sequences that encode a leader sequence, such as for example an immunoglobulin leader, such as the IgE leader. In some embodiments, fragments are free of coding sequences that encode a leader sequence.

Self-Assembling Nanoparticles

[0069] In one embodiment, one or more stabilized spike antigen is incorporated into a self-assembling peptide nanoparticle (SAPN). Self-assembling protein nanoparticles (SAPN) may be formed by the assembly of one or more polypeptide chains comprising at least one antigen and at least one protein oligomerization domain. Without limita-

tion, the SAPN of the invention may self-assemble into a tetrahedron, a cube, an octahedron, a dodecahedron, or an icosahedron. The SAPN of the invention may be used as an efficient means for presenting one or more SARS-COV-2 antigen.

[0070] In one embodiment, the invention relates to a self-assembling nanoparticle comprising an oligomerization domain and further comprising a stabilized spike antigen, a fragment thereof, a variant thereof, or a combination thereof.

[0071] In one embodiment, the invention relates to a nucleic acid molecule encoding a stabilized spike antigen self-assembling nanoparticle, a fragment thereof, a variant thereof, or a combination thereof.

Leader Sequence

[0072] In some embodiments, the stabilized spike antigen sequences of the invention are operably linked to at least one leader sequence or a pharmaceutically acceptable salt thereof. In some embodiments, the nucleic acid molecules of the invention encoding the stabilized spike antigen sequences are operably linked to at least one nucleotide sequence encoding a leader sequence or a pharmaceutically acceptable salt thereof. “Signal peptide” and “leader sequence” are used interchangeably herein and refer to an amino acid sequence that can be linked at the amino terminus of a protein set forth herein. Signal peptides/leader sequences typically direct localization of a protein. Signal peptides/leader sequences used herein preferably facilitate secretion of the protein from the cell in which it is produced. Signal peptides/leader sequences are often cleaved from the remainder of the protein, often referred to as the mature protein, upon secretion from the cell. Signal peptides/leader sequences are linked at the N terminus of the protein.

Linker Sequence

[0073] In some embodiments, the stabilized spike antigen of the invention is operably linked to at least one linker sequence. A linker can be either flexible or rigid or a combination thereof. In one embodiment, the linker is a (GGG)_n, repeat wherein, the GGG is repeated at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more than 10 times.

Vector

[0074] In one embodiment, the invention relates to one or more vectors that include a nucleic acid encoding the stabilized spike antigen. The one or more vectors can be capable of expressing the stabilized spike antigen. The vector can have a nucleic acid sequence containing an origin of replication. The vector can be a plasmid, bacteriophage, bacterial artificial chromosome or yeast artificial chromosome. The vector can be either a self-replicating extrachromosomal vector or a vector which integrates into a host genome.

[0075] The one or more vectors can be an expression construct, which is generally a plasmid that is used to introduce a specific gene into a target cell. Once the expression vector is inside the cell, the protein that is encoded by the gene is produced by the cellular-transcription and translation machinery ribosomal complexes. The plasmid is frequently engineered to contain regulatory sequences that act as enhancer and promoter regions and lead to efficient transcription of the gene carried on the expression vector.

The vectors of the present invention express large amounts of stable messenger RNA, and therefore proteins.

[0076] The vectors may have expression signals such as a strong promoter, a strong termination codon, adjustment of the distance between the promoter and the cloned gene, and the insertion of a transcription termination sequence and a PTIS (portable translation initiation sequence).

(1) Expression Vectors

[0077] The vector can be a circular plasmid or a linear nucleic acid. The circular plasmid and linear nucleic acid are capable of directing expression of a particular nucleotide sequence in an appropriate subject cell. The vector can have a promoter operably linked to the antigen-encoding nucleotide sequence, which may be operably linked to termination signals. The vector can also contain sequences required for proper translation of the nucleotide sequence. The vector comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter, which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development.

(2) Circular and Linear Vectors

[0078] The vector may be a circular plasmid, which may transform a target cell by integration into the cellular genome or exist extrachromosomally (e.g., autonomous replicating plasmid with an origin of replication).

[0079] The vector can be pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing DNA encoding the antigen and enabling a cell to translate the sequence to an antigen that is recognized by the immune system.

[0080] Also provided herein is a linear nucleic acid vaccine, or linear expression cassette ("LEC"), that is capable of being efficiently delivered to a subject via electroporation and expressing one or more desired antigens. The LEC may be any linear DNA devoid of any phosphate backbone. The DNA may encode one or more antigens. The LEC may contain a promoter, an intron, a stop codon, and/or a polyadenylation signal. The expression of the antigen may be controlled by the promoter. The LEC may not contain any antibiotic resistance genes and/or a phosphate backbone. The LEC may not contain other nucleic acid sequences unrelated to the desired antigen gene expression.

(3) Promoter, Intron, Stop Codon, and Polyadenylation Signal

[0081] The vector may have a promoter. A promoter may be any promoter that is capable of driving gene expression and regulating expression of the isolated nucleic acid. Such a promoter is a cis-acting sequence element required for transcription via a DNA dependent RNA polymerase, which transcribes the antigen sequence described herein. Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter may be positioned about the same distance from the transcription start in the vector as it is from the tran-

scription start site in its natural setting. However, variation in this distance may be accommodated without loss of promoter function.

[0082] The promoter may be operably linked to the nucleic acid sequence encoding the antigen and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. The promoter may be a CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or another promoter shown effective for expression in eukaryotic cells.

[0083] The vector may include an enhancer and an intron with functional splice donor and acceptor sites. The vector may contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

Immunogenic Composition

[0084] Provided herein are immunogenic compositions, such as vaccines, comprising a stabilized spike antigen, a nucleic acid molecule encoding a stabilized spike antigen, a fragment thereof, a variant thereof, or a combination thereof. The immunogenic composition can be used to treat SARS-COV-2 infection, thereby treating, preventing, and/or protecting against SARS-COV-2 based pathologies. In one embodiment, the SARS-COV-2 based pathology is COVID-19. The vaccine can significantly induce an immune response of a subject administered the vaccine, thereby protecting against and treating SARS-COV-2 infection.

[0085] The immunogenic composition can be a DNA vaccine, an RNA vaccine, a peptide vaccine, or a combination thereof. The immunogenic composition can include a nucleic acid molecule comprising a sequence encoding the stabilized spike antigen in the form of a lipid nanoparticle or self-assembling nanoparticle. The nucleic acid sequence can be DNA, RNA, cDNA, a variant thereof, a fragment thereof, or a combination thereof. The nucleic acid sequence can also include additional sequences that encode linker, leader, or tag sequences that are linked to the SARS-COV-2 antigen by a peptide bond.

[0086] The immunogenic composition can induce a humoral immune response in the subject administered the immunogenic composition. The induced humoral immune response can be specific for the SARS-COV-2 antigen. The induced humoral immune response can be reactive with the SARS-COV-2 antigen. The humoral immune response can be induced in the subject administered the immunogenic composition by about 1.5-fold to about 16-fold, about 2-fold to about 12-fold, or about 3-fold to about 10-fold. The humoral immune response can be induced in the subject administered the immunogenic composition by at least about 1.5-fold, at least about 2.0-fold, at least about 2.5-fold, at least about 3.0-fold, at least about 3.5-fold, at least about 4.0-fold, at least about 4.5-fold, at least about 5.0-fold, at least about 5.5-fold, at least about 6.0-fold, at least about 6.5-fold, at least about 7.0-fold, at least about 7.5-fold, at least about 8.0-fold, at least about 8.5-fold, at least about 9.0-fold, at least about 9.5-fold, at least about 10.0-fold, at least about 10.5-fold, at least about 11.0-fold, at least about 11.5-fold, at least about 12.0-fold, at least about 12.5-fold, at least about 13.0-fold, at least about 13.5-fold, at least

about 14.0-fold, at least about 14.5-fold, at least about 15.0-fold, at least about 15.5-fold, or at least about 16.0-fold.

[0087] The humoral immune response induced by the immunogenic composition can include an increased level of neutralizing antibodies associated with the subject administered the immunogenic composition as compared to a subject not administered the immunogenic composition. The neutralizing antibodies can be specific for the SARS-COV-2 antigen. The neutralizing antibodies can be reactive with the SARS-COV-2 antigen. The neutralizing antibodies can provide protection against and/or treatment of SARS-COV-2 infection and its associated pathologies in the subject administered the immunogenic composition.

[0088] The humoral immune response induced by the immunogenic composition can include an increased level of IgG antibodies associated with the subject administered the immunogenic composition as compared to a subject not administered the immunogenic composition. These IgG antibodies can be specific for the SARS-COV-2 antigen. These IgG antibodies can be reactive with the SARS-COV-2 antigen. Preferably, the humoral response is cross-reactive against two or more strains of the SARS-COV-2. The level of IgG antibody associated with the subject administered the immunogenic composition can be increased by about 1.5-fold to about 16-fold, about 2-fold to about 12-fold, or about 3-fold to about 10-fold as compared to the subject not administered the immunogenic composition. The level of IgG antibody associated with the subject administered the immunogenic composition can be increased by at least about 1.5-fold, at least about 2.0-fold, at least about 2.5-fold, at least about 3.0-fold, at least about 3.5-fold, at least about 4.0-fold, at least about 4.5-fold, at least about 5.0-fold, at least about 5.5-fold, at least about 6.0-fold, at least about 6.5-fold, at least about 7.0-fold, at least about 7.5-fold, at least about 8.0-fold, at least about 8.5-fold, at least about 9.0-fold, at least about 9.5-fold, at least about 10.0-fold, at least about 10.5-fold, at least about 11.0-fold, at least about 11.5-fold, at least about 12.0-fold, at least about 12.5-fold, at least about 13.0-fold, at least about 13.5-fold, at least about 14.0-fold, at least about 14.5-fold, at least about 15.0-fold, at least about 15.5-fold, or at least about 16.0-fold as compared to the subject not administered the immunogenic composition.

[0089] The immunogenic composition can induce a cellular immune response in the subject administered the immunogenic composition. The induced cellular immune response can be specific for the SARS-COV-2 antigen. The induced cellular immune response can be reactive to the SARS-COV-2 antigen. Preferably, the cellular response is cross-reactive against two or more strains of the SARS-COV-2. The induced cellular immune response can include eliciting a CD8⁺ T cell response. The elicited CD8⁺ T cell response can be reactive with the SARS-COV-2 antigen. The elicited CD8⁺ T cell response can be polyfunctional. The induced cellular immune response can include eliciting a CD8⁺ T cell response, in which the CD8⁺ T cells produce interferon-gamma (IFN- γ), tumor necrosis factor alpha (TNF- α), interleukin-2 (IL-2), or a combination of IFN- γ and TNF- α .

[0090] The induced cellular immune response can include an increased CD8⁺ T cell response associated with the subject administered the immunogenic composition as compared to the subject not administered the immunogenic

composition. The CD8⁺ T cell response associated with the subject administered the immunogenic composition can be increased by about 2-fold to about 30-fold, about 3-fold to about 25-fold, or about 4-fold to about 20-fold as compared to the subject not administered the immunogenic composition. The CD8⁺ T cell response associated with the subject administered the immunogenic composition can be increased by at least about 1.5-fold, at least about 2.0-fold, at least about 3.0-fold, at least about 4.0-fold, at least about 5.0-fold, at least about 6.0-fold, at least about 6.5-fold, at least about 7.0-fold, at least about 7.5-fold, at least about 8.0-fold, at least about 8.5-fold, at least about 9.0-fold, at least about 9.5-fold, at least about 10.0-fold, at least about 10.5-fold, at least about 11.0-fold, at least about 11.5-fold, at least about 12.0-fold, at least about 12.5-fold, at least about 13.0-fold, at least about 13.5-fold, at least about 14.0-fold, at least about 14.5-fold, at least about 15.0-fold, at least about 16.0-fold, at least about 17.0-fold, at least about 18.0-fold, at least about 19.0-fold, at least about 20.0-fold, at least about 21.0-fold, at least about 22.0-fold, at least about 23.0-fold, at least about 24.0-fold, at least about 25.0-fold, at least about 26.0-fold, at least about 27.0-fold, at least about 28.0-fold, at least about 29.0-fold, or at least about 30.0-fold as compared to the subject not administered the immunogenic composition.

[0091] The induced cellular immune response can include an increased frequency of CD3⁺CD8⁺ T cells that produce IFN- γ . The frequency of CD3⁺CD8⁺IFN- γ T cells associated with the subject administered the immunogenic composition can be increased by at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold as compared to the subject not administered the immunogenic composition.

[0092] The induced cellular immune response can include an increased frequency of CD3⁺CD8⁺ T cells that produce TNF- α . The frequency of CD3⁺CD8⁺TNF- α T cells associated with the subject administered the immunogenic composition can be increased by at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, or 14-fold as compared to the subject not administered the immunogenic composition.

[0093] The induced cellular immune response can include an increased frequency of CD3⁺CD8⁺ T cells that produce IL-2. The frequency of CD3⁺CD8⁺IL-2⁺ T cells associated with the subject administered the immunogenic composition can be increased by at least about 0.5-fold, 1.0-fold, 1.5-fold, 2.0-fold, 2.5-fold, 3.0-fold, 3.5-fold, 4.0-fold, 4.5-fold, or 5.0-fold as compared to the subject not administered the immunogenic composition.

[0094] The induced cellular immune response can include an increased frequency of CD3⁺CD8⁺ T cells that produce both IFN- γ and TNF- α . The frequency of CD3⁺CD8⁺IFN- γ ⁺TNF- α ⁺ T cells associated with the subject administered the immunogenic composition can be increased by at least about 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold, 150-fold, 160-fold, 170-fold, or 180-fold as compared to the subject not administered the immunogenic composition.

[0095] The cellular immune response induced by the immunogenic composition can include eliciting a CD4⁺ T cell response. The elicited CD4⁺ T cell response can be

reactive with the SARS-COV-2 antigen. The elicited CD4⁺ T cell response can be polyfunctional. The induced cellular immune response can include eliciting a CD4⁺ T cell response, in which the CD4⁺ T cells produce IFN- γ , TNF- α , IL-2, or a combination of IFN- γ and TNF- α .

[0096] The induced cellular immune response can include an increased frequency of CD3⁺CD4⁺ T cells that produce IFN- γ . The frequency of CD3⁺CD4⁺IFN- γ ⁺ T cells associated with the subject administered the immunogenic composition can be increased by at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold as compared to the subject not administered the immunogenic composition.

[0097] The induced cellular immune response can include an increased frequency of CD3⁺CD4⁺ T cells that produce TNF- α . The frequency of CD3⁺CD4⁺TNF- α ⁺ T cells associated with the subject administered the immunogenic composition can be increased by at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, or 22-fold as compared to the subject not administered the immunogenic composition.

[0098] The induced cellular immune response can include an increased frequency of CD3⁺CD4⁺ T cells that produce IL-2. The frequency of CD3⁺CD4⁺IL-2⁺ T cells associated with the subject administered the immunogenic composition can be increased by at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 26-fold, 27-fold, 28-fold, 29-fold, 30-fold, 31-fold, 32-fold, 33-fold, 34-fold, 35-fold, 36-fold, 37-fold, 38-fold, 39-fold, 40-fold, 45-fold, 50-fold, 55-fold, or 60-fold as compared to the subject not administered the immunogenic composition.

[0099] The induced cellular immune response can include an increased frequency of CD3⁺CD4⁺ T cells that produce both IFN- γ and TNF- α . The frequency of CD3⁺CD4⁺IFN- γ ⁺TNF- α ⁺ associated with the subject administered the immunogenic composition can be increased by at least about 2-fold, 2.5-fold, 3.0-fold, 3.5-fold, 4.0-fold, 4.5-fold, 5.0-fold, 5.5-fold, 6.0-fold, 6.5-fold, 7.0-fold, 7.5-fold, 8.0-fold, 8.5-fold, 9.0-fold, 9.5-fold, 10.0-fold, 10.5-fold, 11.0-fold, 11.5-fold, 12.0-fold, 12.5-fold, 13.0-fold, 13.5-fold, 14.0-fold, 14.5-fold, 15.0-fold, 15.5-fold, 16.0-fold, 16.5-fold, 17.0-fold, 17.5-fold, 18.0-fold, 18.5-fold, 19.0-fold, 19.5-fold, 20.0-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 26-fold, 27-fold, 28-fold, 29-fold, 30-fold, 31-fold, 32-fold, 33-fold, 34-fold, or 35-fold as compared to the subject not administered the immunogenic composition.

[0100] The immunogenic composition of the present invention can have features required of effective vaccines such as being safe so the immunogenic composition itself does not cause illness or death; is protective against illness resulting from exposure to live pathogens such as viruses or bacteria; induces neutralizing antibody to prevent invention of cells; induces protective T cells against intracellular pathogens; and provides ease of administration, few side effects, biological stability, and low cost per dose.

[0101] The immunogenic composition can further induce an immune response when administered to different tissues such as the muscle or skin. The immunogenic composition

can further induce an immune response when administered via electroporation, or injection, or subcutaneously, or intramuscularly.

Excipients and Other Components of the Immunogenic Composition

[0102] A composition comprising a stabilized spike antigen of the invention, or nucleic acid molecule encoding the same (e.g., a vaccine of the invention), may further comprise a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient can be functional molecules such as vehicles, carriers, or diluents. The pharmaceutically acceptable excipient can be a transfection facilitating agent, which can include surface active agents, such as immune-stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents.

[0103] The transfection facilitating agent is a polyanion, polycation, including poly-L-glutamate (LGS), or lipid. The transfection facilitating agent is poly-L-glutamate, and the poly-L-glutamate may be present in the vaccine at a concentration less than 6 mg/ml. The transfection facilitating agent may also include surface active agents such as immune-stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs and vesicles such as squalene and squalene, and hyaluronic acid may also be used administered in conjunction with the genetic construct. The DNA plasmid vaccines may also include a transfection facilitating agent such as lipids, liposomes, including lecithin liposomes or other liposomes known in the art, as a DNA-liposome mixture (see for example W09324640), calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents. The transfection facilitating agent is a polyanion, polycation, including poly-L-glutamate (LGS), or lipid.

[0104] Concentration of the transfection agent in the vaccine is less than 4 mg/ml, less than 2 mg/ml, less than 1 mg/ml, less than 0.750 mg/ml, less than 0.500 mg/ml, less than 0.250 mg/ml, less than 0.100 mg/ml, less than 0.050 mg/ml, or less than 0.010 mg/ml.

[0105] The pharmaceutically acceptable excipient can be an adjuvant. The adjuvant can be other genes that are expressed in an alternative plasmid or are delivered as proteins in combination with the plasmid above in the vaccine. The adjuvant may be selected from the group consisting of: α -interferon (IFN- α), β -interferon (IFN- β), γ -interferon, platelet derived growth factor (PDGF), TNF α , TNF β , GM-CSF, epidermal growth factor (EGF), cutaneous T cell-attracting chemokine (CTACK), epithelial thymus-expressed chemokine (TECK), mucosae-associated epithelial chemokine (MEC), IL-12, IL-15, MHC, CD80, CD86 including IL-15 having the signal sequence deleted and optionally including the signal peptide from IgE. The adjuvant can be IL-12, IL-15, IL-28, CTACK, TECK, platelet derived growth factor (PDGF), TNF α , TNF β , GM-CSF, epidermal growth factor (EGF), IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, or a combination thereof.

[0106] Other genes that can be useful as adjuvants include those encoding: MCP-1, MIP-1a, MIP-1p, IL-8, RANTES,

L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, Mad-CAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, IL-4, mutant forms of IL-18, CD40, CD40L, vascular growth factor, fibroblast growth factor, IL-7, IL-22, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, I κ B, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NF κ B, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

[0107] The vaccine may further comprise a genetic vaccine facilitator agent as described in U.S. Ser. No. 021,579 filed Apr. 1, 1994, which is fully incorporated by reference.

[0108] The vaccine can be formulated according to the mode of administration to be used. An injectable vaccine pharmaceutical composition can be sterile, pyrogen free and particulate free. An isotonic formulation or solution can be used. Additives for isotonicity can include sodium chloride, dextrose, mannitol, sorbitol, and lactose. The vaccine can comprise a vasoconstriction agent. The isotonic solutions can include phosphate buffered saline. Vaccine can further comprise stabilizers including gelatin and albumin. The stabilizers can allow the formulation to be stable at room or ambient temperature for extended periods of time, including LGS or polycations or polyanions.

4. Method of Vaccination

[0109] Also provided herein is a method of treating, protecting against, and/or preventing disease in a subject in need thereof by administering the stabilized spike antigen of the invention to the subject or nucleic acid molecules encoding the same. Administration of the stabilized spike antigen, or nucleic acid molecules encoding the same, of the invention to the subject can induce or elicit an immune response in the subject. The induced immune response can be used to treat, prevent, and/or protect against disease, for example, pathologies relating to SARS-COV-2 infection. In one embodiment, the pathology relating to SARS-COV-2 infection is COVID-19.

[0110] The induced immune response can include an induced humoral immune response and/or an induced cellular immune response. The humoral immune response can be induced by about 1.5-fold to about 16-fold, about 2-fold to about 12-fold, or about 3-fold to about 10-fold. The induced humoral immune response can include IgG antibodies and/or neutralizing antibodies that are reactive to the SARS-COV-2 spike RBD. The induced cellular immune response can include a CD8⁺ T cell response, which is induced by about 2-fold to about 30-fold, about 3-fold to about 25-fold, or about 4-fold to about 20-fold.

[0111] The dose of the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be between 1 μ g to 10 mg active component/kg body weight/time, and can be 20 μ g to 10 mg component/kg body weight/time. The vaccine can be administered every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,

22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days. The number of vaccine doses for effective treatment can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Administration

[0112] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be formulated in accordance with standard techniques well known to those skilled in the pharmaceutical art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the age, sex, weight, and condition of the particular subject, and the route of administration. The subject can be a mammal, such as a human, a horse, a cow, a pig, a sheep, a cat, a dog, a rat, or a mouse.

[0113] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be administered prophylactically or therapeutically. In prophylactic administration, the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be administered in an amount sufficient to induce an immune response. In therapeutic applications, the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, are administered to a subject in need thereof in an amount sufficient to elicit a therapeutic effect. An amount adequate to accomplish this is defined as “therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the particular composition of the therapeutic regimen administered, the manner of administration, the stage and severity of the disease, the general state of health of the patient, and the judgment of the prescribing physician.

[0114] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be administered by methods well known in the art as described in Donnelly et al. (Ann. Rev. Immunol. 15:617-648 (1997)); Felgner et al. (U.S. Pat. No. 5,580,859, issued Dec. 3, 1996); Felgner (U.S. Pat. No. 5,703,055, issued Dec. 30, 1997); and Carson et al. (U.S. Pat. No. 5,679,647, issued Oct. 21, 1997), the contents of all of which are incorporated herein by reference in their entirety. In some embodiments, DNA molecules can be complexed to particles or beads that can be administered to an individual, for example, using a vaccine gun. One skilled in the art would know that the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration of the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same.

[0115] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be delivered via a variety of routes. Typical delivery routes include parenteral administration, e.g., intradermal, intramuscular or subcutaneous delivery. Other routes include oral administration, intranasal, and intravaginal routes. In some embodiments, nucleic acid molecules can be delivered to the interstitial spaces of tissues of an individual (Felgner et al., U.S. Pat. Nos. 5,580,859 and 5,703,055, the contents of all of which are incorporated herein by reference in their entirety). The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can also be administered to muscle, or can be administered via intradermal or subcutaneous injections, or transdermally, such as by iontophoresis. Epidermal administration of the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can also be employed. Epidermal admin-

istration can involve mechanically or chemically irritating the outermost layer of epidermis to stimulate an immune response to the irritant (Carson et al., U.S. Pat. No. 5,679,647, the contents of which are incorporated herein by reference in its entirety).

[0116] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can also be formulated for administration via the nasal passages.

[0117] Formulations suitable for nasal administration, wherein the carrier is a solid, can include a coarse powder having a particle size, for example, in the range of about 10 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. The formulation can be a nasal spray, nasal drops, or by aerosol administration by nebulizer. The formulation can include aqueous or oily solutions of the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same.

[0118] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be a liquid preparation such as a suspension, syrup or elixir. The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can also be a preparation for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration), such as a sterile suspension or emulsion.

[0119] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be incorporated into liposomes, microspheres or other polymer matrices (Felgner et al., U.S. Pat. No. 5,703,055; Gregoriadis, *Liposome Technology*, Vols. I to III (2nd ed. 1993), the contents of which are incorporated herein by reference in their entirety). Liposomes can consist of phospholipids or other lipids, and can be nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

[0120] The stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, can be administered via electroporation, such as by a method described in U.S. Pat. No. 7,664,545, the contents of which are incorporated herein by reference. The electroporation can be by a method and/or apparatus described in U.S. Pat. Nos. 6,302,874; 5,676,646; 6,241,701; 6,233,482; 6,216,034; 6,208,893; 6,192,270; 6,181,964; 6,150,148; 6,120,493; 6,096,020; 6,068,650; and 5,702,359, the contents of which are incorporated herein by reference in their entirety. The electroporation may be carried out via a minimally invasive device.

[0121] The minimally invasive electroporation device ("MID") may be an apparatus for injecting the vaccine described above and associated fluid into body tissue. The device may comprise a hollow needle, DNA cassette, and fluid delivery means, wherein the device is adapted to actuate the fluid delivery means in use so as to concurrently (for example, automatically) inject DNA into body tissue during insertion of the needle into the said body tissue. This has the advantage that the ability to inject the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, and associated fluid gradually while the needle is being inserted leads to a more even distribution of the fluid through the body tissue. The pain experienced during injection may be reduced due to the distribution of

the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, being injected over a larger area.

[0122] The MID may inject the stabilized spike antigen of the invention, or nucleic acid molecules encoding the same, into tissue without the use of a needle. The MID may inject the vaccine as a small stream or jet with such force that the vaccine pierces the surface of the tissue and enters the underlying tissue and/or muscle. The force behind the small stream or jet may be provided by expansion of a compressed gas, such as carbon dioxide through a micro-orifice within a fraction of a second. Examples of minimally invasive electroporation devices, and methods of using them, are described in published U.S. Patent Application No. 20080234655; U.S. Pat. Nos. 6,520,950; 7,171,264; 6,208,893; 6,009,347; 6,120,493; 7,245,963; 7,328,064; and 6,763,264, the contents of each of which are herein incorporated by reference.

[0123] The MID may comprise an injector that creates a high-speed jet of liquid that painlessly pierces the tissue. Such needle-free injectors are commercially available. Examples of needle-free injectors that can be utilized herein include those described in U.S. Pat. Nos. 3,805,783; 4,447,223; 5,505,697; and 4,342,310, the contents of each of which are herein incorporated by reference.

[0124] A desired vaccine in a form suitable for direct or indirect electrotransport may be introduced (e.g., injected) using a needle-free injector into the tissue to be treated, usually by contacting the tissue surface with the injector so as to actuate delivery of a jet of the agent, with sufficient force to cause penetration of the vaccine into the tissue. For example, if the tissue to be treated is mucosa, skin or muscle, the agent is projected towards the mucosal or skin surface with sufficient force to cause the agent to penetrate through the stratum corneum and into dermal layers, or into underlying tissue and muscle, respectively.

[0125] Needle-free injectors are well suited to deliver vaccines to all types of tissues, particularly to skin and mucosa. In some embodiments, a needle-free injector may be used to propel a liquid that contains the vaccine to the surface and into the subject's skin or mucosa. Representative examples of the various types of tissues that can be treated using the invention methods include pancreas, larynx, nasopharynx, hypopharynx, oropharynx, lip, throat, lung, heart, kidney, muscle, breast, colon, prostate, thymus, testis, skin, mucosal tissue, ovary, blood vessels, or any combination thereof.

[0126] The MID may have needle electrodes that electroporate the tissue. By pulsing between multiple pairs of electrodes in a multiple electrode array, for example set up in rectangular or square patterns, provides improved results over that of pulsing between a pair of electrodes. Disclosed, for example, in U.S. Pat. No. 5,702,359 entitled "Needle Electrodes for Mediated Delivery of Drugs and Genes" is an array of needles wherein a plurality of pairs of needles may be pulsed during the therapeutic treatment. In that application, which is incorporated herein by reference as though fully set forth, needles were disposed in a circular array, but have connectors and switching apparatus enabling a pulsing between opposing pairs of needle electrodes. A pair of needle electrodes for delivering recombinant expression vectors to cells may be used. Such a device and system is described in U.S. Pat. No. 6,763,264, the contents of which are herein incorporated by reference. Alternatively, a single

needle device may be used that allows injection of the DNA and electroporation with a single needle resembling a normal injection needle and applies pulses of lower voltage than those delivered by presently used devices, thus reducing the electrical sensation experienced by the patient.

[0127] The MID may comprise one or more electrode arrays. The arrays may comprise two or more needles of the same diameter or different diameters. The needles may be evenly or unevenly spaced apart. The needles may be between 0.005 inches and 0.03 inches, between 0.01 inches and 0.025 inches; or between 0.015 inches and 0.020 inches. The needle may be 0.0175 inches in diameter. The needles may be 0.5 mm, 1.0 mm, 1.5 mm, 2.0 mm, 2.5 mm, 3.0 mm, 3.5 mm, 4.0 mm, or more spaced apart.

[0128] The MID may consist of a pulse generator and a two or more-needle vaccine injectors that deliver the vaccine and electroporation pulses in a single step. The pulse generator may allow for flexible programming of pulse and injection parameters via a flash card operated personal computer, as well as comprehensive recording and storage of electroporation and patient data. The pulse generator may deliver a variety of volt pulses during short periods of time. For example, the pulse generator may deliver three 15 volt pulses of 100 ms in duration. An example of such a MID is the Elgen 1000 system by Inovio Biomedical Corporation, which is described in U.S. Pat. No. 7,328,064, the contents of which are herein incorporated by reference.

[0129] The MID may be a CELLECTRA (Inovio Pharmaceuticals, Blue Bell PA) device and system, which is a modular electrode system, that facilitates the introduction of a macromolecule, such as a DNA, into cells of a selected tissue in a body or plant. The modular electrode system may comprise a plurality of needle electrodes; a hypodermic needle; an electrical connector that provides a conductive link from a programmable constant-current pulse controller to the plurality of needle electrodes; and a power source. An operator can grasp the plurality of needle electrodes that are mounted on a support structure and firmly insert them into the selected tissue in a body or plant. The macromolecules are then delivered via the hypodermic needle into the selected tissue. The programmable constant-current pulse controller is activated and constant-current electrical pulse is applied to the plurality of needle electrodes. The applied constant-current electrical pulse facilitates the introduction of the macromolecule into the cell between the plurality of electrodes. Cell death due to overheating of cells is minimized by limiting the power dissipation in the tissue by virtue of constant-current pulses. The Cellectra device and system is described in U.S. Pat. No. 7,245,963, the contents of which are herein incorporated by reference.

[0130] The MID may be an Elgen 1000 system (Inovio Pharmaceuticals). The Elgen 1000 system may comprise device that provides a hollow needle; and fluid delivery means, wherein the apparatus is adapted to actuate the fluid delivery means in use so as to concurrently (for example automatically) inject fluid, the described vaccine herein, into body tissue during insertion of the needle into the said body tissue. The advantage is the ability to inject the fluid gradually while the needle is being inserted leads to a more even distribution of the fluid through the body tissue. It is also believed that the pain experienced during injection is reduced due to the distribution of the volume of fluid being injected over a larger area.

[0131] In addition, the automatic injection of fluid facilitates automatic monitoring and registration of an actual dose of fluid injected. This data can be stored by a control unit for documentation purposes if desired.

[0132] It will be appreciated that the rate of injection could be either linear or non-linear and that the injection may be carried out after the needles have been inserted through the skin of the subject to be treated and while they are inserted further into the body tissue.

[0133] Suitable tissues into which fluid may be injected by the apparatus of the present invention include tumor tissue, skin or liver tissue but may be muscle tissue.

[0134] The apparatus further comprises needle insertion means for guiding insertion of the needle into the body tissue. The rate of fluid injection is controlled by the rate of needle insertion. This has the advantage that both the needle insertion and injection of fluid can be controlled such that the rate of insertion can be matched to the rate of injection as desired. It also makes the apparatus easier for a user to operate. If desired means for automatically inserting the needle into body tissue could be provided.

[0135] A user could choose when to commence injection of fluid. Ideally however, injection is commenced when the tip of the needle has reached muscle tissue and the apparatus may include means for sensing when the needle has been inserted to a sufficient depth for injection of the fluid to commence. This means that injection of fluid can be prompted to commence automatically when the needle has reached a desired depth (which will normally be the depth at which muscle tissue begins). The depth at which muscle tissue begins could for example be taken to be a preset needle insertion depth such as a value of 4 mm which would be deemed sufficient for the needle to get through the skin layer.

[0136] The sensing means may comprise an ultrasound probe. The sensing means may comprise a means for sensing a change in impedance or resistance. In this case, the means may not as such record the depth of the needle in the body tissue but will rather be adapted to sense a change in impedance or resistance as the needle moves from a different type of body tissue into muscle. Either of these alternatives provides a relatively accurate and simple to operate means of sensing that injection may commence. The depth of insertion of the needle can further be recorded if desired and could be used to control injection of fluid such that the volume of fluid to be injected is determined as the depth of needle insertion is being recorded.

[0137] The apparatus may further comprise: a base for supporting the needle; and a housing for receiving the base therein, wherein the base is moveable relative to the housing such that the needle is retracted within the housing when the base is in a first rearward position relative to the housing and the needle extends out of the housing when the base is in a second forward position within the housing. This is advantageous for a user as the housing can be lined up on the skin of a patient, and the needles can then be inserted into the patient's skin by moving the housing relative to the base.

[0138] As stated above, it is desirable to achieve a controlled rate of fluid injection such that the fluid is evenly distributed over the length of the needle as it is inserted into the skin. The fluid delivery means may comprise piston driving means adapted to inject fluid at a controlled rate. The piston driving means could for example be activated by a servo motor. However, the piston driving means may be

actuated by the base being moved in the axial direction relative to the housing. It will be appreciated that alternative means for fluid delivery could be provided. Thus, for example, a closed container which can be squeezed for fluid delivery at a controlled or non-controlled rate could be provided in the place of a syringe and piston system.

[0139] The apparatus described above could be used for any type of injection. It is however envisaged to be particularly useful in the field of electroporation and so it may further comprises means for applying a voltage to the needle. This allows the needle to be used not only for injection but also as an electrode during, electroporation. This is particularly advantageous as it means that the electric field is applied to the same area as the injected fluid. There has traditionally been a problem with electroporation in that it is very difficult to accurately align an electrode with previously injected fluid and so users have tended to inject a larger volume of fluid than is required over a larger area and to apply an electric field over a higher area to attempt to guarantee an overlap between the injected substance and the electric field. Using the present invention, both the volume of fluid injected and the size of electric field applied may be reduced while achieving a good fit between the electric field and the fluid.

5. Kit

[0140] Provided herein is a kit, which can be used for treating a subject using the method of vaccination described above. In one embodiment, the kit can comprise the vaccine. In one embodiment, the kit can comprise a nucleic acid molecule encoding a stabilized spike antigen of the invention.

[0141] The kit can also comprise instructions for carrying out the vaccination method described above and/or how to

use the kit. Instructions included in the kit can be affixed to packaging material or can be included as a package insert. While instructions are typically written or printed materials, they are not limited to such. Any medium capable of storing instructions and communicating them to an end user is contemplated by this disclosure. Such media include, but are not limited to, links to websites, QR codes, electronic storage media (e.g., magnetic discs, tapes, cartridges), optical media (e.g., CD ROM), and the like. As used herein, the term "instructions" can include the address of an internet site which provides instructions.

[0142] The present invention has multiple aspects, illustrated by the following non-limiting examples.

EXAMPLES

Example 1

Structure-Based Vaccine Design for SARS COV-2

Structure-Based Design can be Employed to Create Spikes with Novel RBD Dynamics

[0143] A structure-guided work-flow illuminated clusters of positions in which a glycan would could be added to a stabilized spike with a low clash score for an RBD in an up conformation and a high clash score when in the down conformation. The clusters were evaluated for potential glycosylation sites and a glycan sugar score was calculated based on native glycoproteins. The design produced a single glycan addition to a stabilized prefusion spike which could force a 100% all up conformation for RBDs and focuses immune response to epitopes A, B and F on RBD (FIG. 1).

Example 2

Sequences

6P_UpG1 SEQ ID NO: 1

ATGTTCTGCTCTCTCGTGGTGTGCTCCCTGGTTTCCAGCCAGTCGCTGAACCT

CACAACTCGTACCCAGCTCCACCCGCTTACCAACTCCTTTACCAGGGGC

GTGTATTACCCAGATAAGGTGTTTCTGTAGCAGCGTGTGCACAGTACCCAGG

ACCTGTTTCTCCCTTTCTTCAGCAATGTCACATGGTTTCACGCCATCCAGTT

TCTGGTACTAATGGTACCAAGCGTTTCGACAACCCCGTGCTCCCGTTTAACG

ATGGTGTCTACTTCGCTTCCACCGAAAGTCCAACATTATCCGTGGCTGGAT

CTTTGGCACCCCTGGATAGCAAAACACAGTCACTGCTGATTGTGAATAAC

GCCACCAACGTCGTGATAAAAGTGTGCGAATTCAGTTTTCGAATGATCCTT

TCCTGGGAGTTTATTATCACAAGAACAACAAAGTTGGATGGAATCCGAGTT

CCGGGTTTATCTCTGCAATAACTGCACCTTCGAGTACGTCTCTCAGCCTT

TTCTCATGGACCTCGAAGGGAAACAAGGAACTTCAAGAATCTGAGGGAAT

TTGTTTTCAGAACATTGACGGGTATTTCAAGATCTACAGCAAGCATACCC

CATTAACTCGTGAGGGACCTGCCACAAGGCTTCTCCGCCTTGAACCACTC

GTCGACCTGCCTATAGGCATTAACATCACCCGATTTTCAGACGCTCCTGGCAT

TGCACCGAAGCTATCTGACACAGGTGATTATCCTCTGGCTGGACGCGCGG

TGCGGCAGCTTATTACGTGGGATATCTGCAGCCTAGGACATTCTGCTCAAG

- continued

TATAATGAGAACGGCACTATCACTGATGCAGTGGACTGTGCCCTTGACCCGC
TCAGTGAGACCAAGTGCACCCCTCAAGTCCTTCACTGTTGAAAAGGGTATCTA
TCAAACCAGCAATTTTAGAGTCCAGCCTACTGAGAGCATTGTCAGATTTCTT
AATATCACAAATCTCTGTCCTTTTGGTGAGGTCTTTAATGCGACCCGCTTCGC
CAGTGTGTATGCTTGGAAATCGTAAGAGAATTAGCAACTGTGTAGCAGACTAT
TCAGTCTTGTACAACCTCCGCCAGCTTTTCTACATTAAAGTGTACGGGGTGAA
CGGCACCAAGTTGAACGATTTGTGCTTCACAAACGTTTACGCCGATAGCTTT
GTTATTAGGGGAGATGAAGTTCGCCAGATTGCCCTGGCCAAACCGGAA
ATTGCGGACTACAACATAAGTTGCCCGACGACTTCACTGGTTGTGTAATCG
CCTGGAACCTCAACAATCTGGACAGTAAGGTAGGTGGCAATTATAACTATTT
GTATCGCCTTTTCCGGAAGTCCAATCTGAAACCTTCGAACGGGACATTTCA
ACTGAAATCTACCAGGCCGGAAGTACGCCATGTAACGGCGTTGAGGGGTTT
AATTGTTACTTCCCCTGCAAAGCTACGGTTTCCAGCCAATAATGGAGTTG
GCTATCAGCCTTACCAGGTGGTGGTTCTTTCTTCGAGCTTTTGCATGCTCCA
GCCACGGTCTGCGGACCAAGAAGTCAACAACTTGGTGAAGAACAATGC
GTAAACTTCAACTTTAACGGTCTCACTGGCACAGGAGTGCTTACGGAGTCCA
ATAAGAAGTTCCTTCCTTTTCAGCAGTTTGGTCGAGACATCGCTGATACAAC
GGATGCTGTAAGAGACCCCGACTTTGGAGATTCTGGACATTACCCCATGC
TCATTTGGCGCGTGTGAGTGATCAGTATCAGTACAGTAACTTCCAATCAGG
TAGCGGTCTTTTACCAGGACGTTAATTGTACCGAAGTACCCGTAGCGATCCA
CGCAGACAGCTGACTCCCACTTGGCGGTTTACAGTACGGGTTCAAACGTT
TTCCAGACCCGTGCTGGATGCCTTATCGGTGCGGAGCATGTAAACAACCTCAT
ACGAATGTGACATCCCTATCGGGCAGGAATATGCGCATCTTACCAAACAC
AGACAAATCTCCAGGCTCAGCATCTTCCGTGGCGTCTCAGAGTATAATCGC
ATATACCATGAGTCTTGGTGCCGAGAATTCAGTCGCGTATTCTAACAATTCT
ATCGCTATCCCAACGAACCTCACAATATCCGTCAACAACGAGATTCTCCCTG
TTCTATGACTAAGACTAGTGTGGATTGTACGATGTATATCTGTGGGATAG
CACAGAATGCAGTAACCTGCTGCTTCACTACGGCTCATTTTGTACCCAACTC
AATAGAGCCCTCACCGGTATAGCCGTGGAACAGGATAAGAATACTCAAGAG
GTGTTTGGCCAGGTGAAGCAAATTTATAAACTCCACCTATTAAGGACTTCG
GTGGATTTAATTTTAGTCAGATTCTCCCGACCTTCCAAACCTAGCAAGCG
GTCCCTTATTGAGGATCTCCTTTTCAACAAAGTGACCTGGCCGACGCGGG
TTCATTAAACAGTACGGAGACTGCCTCGGTGACATAGCCGCACGCGATCTTA
TCTGTGCACAGAAATTTAACGGTCTTACCGTCCTTCCGCCACTGTTGACAGA
TGAAATGATCGCCCAATACACCTCAGCATTGCTGGCTGGTACCATTACTTCT
GGATGGACATTTGGTGCAGGACCCGCTCTGCAGATCCCTTCCCTATGCAGA
TGGCATAACAGATTCAACGGAATTGGAGTCACTCAGAATGTTCTGTACGAGAA
TCAAAGTTGATTGCCAACAGTTTAACTCCGCAATTGGTAAGATACAAGAC
AGCCTCTCTTCTACTCCCTCCGCGTTGGGAAAGCTGCAGGATGTGGTGAATC

-continued

AGAACGCACAGGCCCTGAATACTCTGGTGAAGCAGTTGAGCTCAAACTTTG
GGCCCATCTCTCCGTCCTCAATGACATACTGAGCAGACTCGATCCCCAGA
GGCTGAGGTGCAGATTGATCGCTTGATCACGGGGAGACTCCAGTCTCTCCAG
ACATATGTAACCTCAGCAGCTGATTAGAGCGGCGGAGATCAGAGCATCCGCC
AACCTTGCCGCTACCAAAATGTCTGAATGCGTGTGGGCCAGTCCAAGCGTG
TGGATTTCTGTGGGAAGGATATCATCTGATGTCATTTCCCAATCAGCTCCT
CACGGCGTTGTTTTCTGCATGTTACCTACGTGCCAGCTCAGGAGAAGAATT
TCACTACCGCGCCTGCCATTTGCCATGACGGCAAGGCGCATTTCCCAGGGA
AGGAGTCTTTGTAGTAATGGTACACACTGGTTCGTACCCAGCGTAATTC
TACGAGCCACAGATTATTACGACAGACAACACTTTCTGTATCCGGTAATTGCG
ACGTAGTCATTGGCATTGTAAATAATACCGTATACGACCCTCTCCAGCCCGA
ACTTGACAGTTTAAAGGAAGAGTTGGATAAATACTTCAAGAACCATACTTCT
CCAGATGTCGACCTGGGTGATATTTCTGGAATCAATGCCTCTGTTGTTAACA
TTCAGAAAGAAATAGATCGGCTCAATGAGGTGCCAAGAATTTGAACGAGT
CACTGATTGACCTGCAGGAGCTCGGAAAGTATGAACAGGGATATATACCAG
AGGCCCCCAGAGATGGCCAGGCCTATGTTTCGCAAGGACGGGAGTGGGTCC
TGCTGTCCACTTTCCTCGGATAATAA

6P_UpG1

SEQ ID NO: 2

MFVFLVLLPLVSSQCVNLTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLF
LPFFSNVTFPHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIRGWIFGTTL
DSKTQSLILVNNATNVVIKVCEQFCNDPFLGVYHKNKSWMESEFRVYSSA
NNCTFEYVSQPFMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPO
GFSALEPLVDLPIGINITRFQTLALHRSYLTPGDSSSGWTAGAAAYVGYLQPR
TFLKYNENGTTIDAVDCALDPLSEKCTLKSFTVEKGIYQTSNFRVQPTESIVRF
PNITNLCPFGEVFNATRFASVYAWNKRISNCVADYSVLNSASFSTFKCYGVN
G_TKLNLDLCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTGCVIAWN
SNNLDSKVGNYNYLYRLFRKSNLKPFERDISTEIQAGSTPCNGVEGENCYFPFL
QSYGFQPTNGVGYPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNPNFNG
LTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTLLEILDITPCSFGGVSVITPG
TNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAE
HVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSI IAYTMSLGAENSVAYSN
NSIAIPTNFTISVTTIELPVSMKTSTVDCTMYICGDSTECNLLQYGSFCTQLNR
ALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSPKSPKRSPIEDL
LFNKVTLADAGFIKQYGDCLGDI AARDLICAQKFNGLTVLPPLLTDEMIAYTS
ALLAGTITSGWTFGAGPALQIPPPMQMAYRENGIGVTQNVLYENQKLIANQFNS
AIGKIQDSLSTSPSALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRL
DPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKR
VDFCGKGYHLSFPQSPHGVVFLHVTYVPAQEKNF TAPAICHGDKAHFPRE
GVFVSNGTHWFVTQRNFYEPQIIITDNTFVSGNCDVVIGVMNTVYDPLQPELDS

-continued

FKEELDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQE

LGKYEQGYIPEAPRDGQAYVRKDGEWVLLSTFLG

6P_UpG1 (with IgE)

SEQ ID NO: 3

ATGGATTGGACGTGGATACTTTTCCTTGTTGCTGCTGCTACCCGCGTAC**ACAGCATGTTCTGCTCTTCCTGGTGTGCTCCCCCTGGTTCCAGCCAGTGCCTG**

AACCTCACAACTCGTACCCAGCTCCACCCGCTTACACCAACTCCTTTACCA

GGGGCGTGTATTACCCAGATAAGGTGTTTCGTAGCAGCGTGCTGCACAGTAC

CCAGGACCTGTTTCTCCCTTTCTTCAGCAATGTCACATGGTTTCACGCCATCC

ACGTTTCTGGTACTAATGGTACCAAGCGTTTCGACAACCCCGTGCTCCCGTTT

AACGATGGTGTCTACTTCGCTTCCACCGAAAAGTCCAACATTATCCGTGGCT

GGATCTTTGGCACCACCCTGGATAGCAAAACACAGTCACTGCTGATTGTGAA

TAACGCCACCAACGTCGTGATAAAAGTGTGCGAATTCAGTTTGAATGAT

CCTTTCCTGGGAGTTTATTATCACAGAACAACAAAAGTTGGATGGAATCCG

AGTTCGGGTTTATTCTCTGCAAATAACTGCACCTTCGAGTACGTCTCTCAG

CCTTTCCTCATGGACCTCGAAGGGAAACAAGGAACTTCAAGAATCTGAGG

GAATTTGTTTTCAAGAACATTGACGGGTATTTCAAGATCTACAGCAAGCATA

CCCCCATTAACCTCGTGAGGGACCTGCCACAAGGCTTCTCCGCTTGGAACC

ACTCGTCGACCTGCCTATAGGCATTAACATCACCCGATTCAGACGCTCCTG

GCATTGCACCGAAGCTATCTGACACCAGGTGATTATCCTCTGGCTGGACGG

CCGGTGCAGCAGCTTATTACGTGGGATATCTGCAGCCTAGGACATTCTGCT

CAAGTATAATGAGAACGGCACTATCACTGATGCAGTGGACTGTGCCCTTGAC

CCGCTCAGTGAGACCAAGTGACCCCTCAAGTCCTTCACTGTTGAAAAGGGTA

TCTATCAAACCAGCAATTTAGAGTCCAGCCTACTGAGAGCATTGTGAGATT

TCCTAATATCACAAATCTCTGCTTTTGGTGAGGTCTTAAATGCGACCCGCT

TCGCCAGTGTGTATGCCTGGAATCGTAAGAGAATTAGCAACTGTGTAGCAGA

CTATTGAGTCTTGTACAACTCCGCCAGCTTTTCTACATTTAAGTGTACGGGG

TG**AACGGC**ACCAAGTTGAACGATTTGTGCTTCACAAACGTTTACGCCGATA

GCTTTGTTATTAGGGGAGATGAAGTTCGCCAGATTGCCCTGGCCAAACCGG

GAAAATTGCGGACTACAACTATAAGTTGCCCGACGACTTCACTGGTTGTGTA

ATCGCCTGGAACCTCAACAATCTGGACAGTAAGGTAGGTGGCAATTATAACT

ATTTGTATCGCCTTTTCCGGAAGTCCAATCTGAAACCTTCGAACGGGACAT

TTCAACTGAAATCTACCAGGCCGGAAGTACGCCATGTAAACGGCGTTGAGGG

GTTCAATTGTTACTTCCCACTGCAAAGCTACGGTTTCCAGCCAATAATGGA

GTTGGCTATCAGCCTTACCGGGTGGTGGTTCTTTCCTTCGAGCTTTTGCATGC

TCCAGCCACGGTCTGCGGACCAAAGAAGTCAACAACTTGGTGAAGAACA

ATGCGTAACCTTCAACTTTAACGGTCTCACTGGCACAGGAGTGCTTACGGAG

TCCAATAAGAAGTTCCTTCCTTTTCAGCAGTTTGGTCGAGACATCGCTGATA

CAACGGATGCTGTAAGAGACCCCGAGCTTTGGAGATTCTGGACATTACCCC

ATGCTCATTTGGCGGCGTGTGAGTGATCACCCAGGTACTAACACTTCCAAT

-continued

CAGGTAGCGGTCCCTTTACCAGGACGTTAATTGTACCGAAGTACCCGTAGCGA
TCCACGCAGACCAGCTGACTCCCACTTGGCGGGTTTACAGTACGGGTTCAAA
CGTTTTCCAGACCCGTGCTGGATGCCTTATCGGTGCGGAGCATGTAAACAAC
TCATACGAATGTGACATCCCTATCGGGGAGGAATATGCGCATCTTACAAA
CACAGACAAATTCTCCAGGCTCAGCATCTTCCGTGGCGTCTCAGAGTATAAT
CGCATATACCATGAGTCTTGGTGCCGAGAATTCAGTCGCGTATTCTAACAAT
TCTATCGCTATCCCAACGAACCTCACAATATCCGTCACAACCGAGATTCTCC
CTGTTTCTATGACTAAGACTAGTGTGGATTGTACGATGTATATCTGTGGGA
TAGCACAGAATGCAGTAACCTGCTGCTTCAGTACGGCTCATTTTGTACCCAA
CTCAATAGAGCCCTCACCGGTATAGCCGTGAACAGGATAAGAATACTCAA
GAGGTGTTTGCCAGGTGAAGCAAATTTATAAACTCCACCTATTAAGGACT
TCGGTGGATTTAATTTTAGTCAGATTCTCCCGACCCCTCCAAACCTAGCAA
GCGGTCCCTATTGAGGATCTCCTTTTCAACAAAGTGACCCGTGGCCGACGCC
GGTTTCATTAAACAGTACGGAGACTGCCTCGGTGACATAGCCGCACGCGAT
CTTATCTGTGCACAGAAATTTAACGGTCTTACCGTCCTTCCGCCACTGTTGAC
AGATGAAATGATCGCCCAATACACCTCAGCATTGCTGGCTGGTACCATTACT
TCTGGATGGACATTTGGTGAGGACCCGCTCTGCAGATCCCTTCCCTATGC
AGATGGCATAACAGATTCAACGGAATTGGAGTCACTCAGAATGTTCTGTACGA
GAATCAAAAGTTGATTGCCAACAGTTTAACTCCGCAATTGGTAAGATACAA
GACAGCCTCTCTTCTACTCCCTCCGCGTTGGGAAAGCTGCAGGATGTGGTGA
ATCAGAACGCACAGGCCCTGAATACTCTGGTGAAGCAGTTGAGCTCAAACTT
TGGGGCCATCTCTTCCGTCCTCAATGACATACTGAGCAGACTCGATCCCCA
GAGGCTGAGGTGCAGATTGATCGCTTGATCACGGGAGACTCCAGTCTCTCC
AGACATATGTAACCTCAGCAGCTGATTAGAGCGGCGGAGATCAGAGCATCCG
CCAACCTTGCCGCTACCAAAATGTCTGAATGCGTGCTGGGCCAGTCCAAGCG
TGTGGATTCTGTGGGAAGGATATCATCTGATGTCATTTCCCAATCAGCT
CCTCACGGCGTTGTTTCTCGCATGTTACCTACGTGCCAGCTCAGGAGAAGA
ATTTCACTACCGCGCTGCCATTGTCATGACGGCAAGGCGCATTTCCTCCAG
GGAAGGAGTCTTTGTTAGTAATGGTACACACTGGTTCGTACCCAGCGTAAT
TTCTACGAGCCACAGATTATTACGACAGACAACACTTTCGTATCCGGTAATT
GCGACGTAGTCATTGGCATTGTAAATAATACCGTATACGACCTCTCCAGCC
CGAACTTGACAGTTTTAAGGAAGAGTTGGATAAATACTTCAAGAACCATACT
TCTCCAGATGTCGACCTGGGTGATATTTCTGGAATCAATGCCTCTGTTGTTAA
CATTCAGAAAGAAATAGATCGGCTCAATGAGGTCGCCAAGAATTTGAACGA

-continued

GTCAGTGAATTGACCTGCAGGAGCTCGGAAAGTATGAACAGGGATATATACC
AGAGGCCCCAGAGATGGCCAGGCCTATGTTTCGCAAGGACGGGGAGTGGGT
CCTGCTGTCCACTTTCCTCGGATAATAA
6P_UpG1 (with IgE) SEQ ID NO: 4
MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRG
VYYPDKVFRSSVLHSTQDLFLPFFSNVTFWFAIHVSGTNGTKRFDNPVLPFNDG
VYFASTEKSNIIIRGWIFGTTLDSTQSLLIIVNNATNVVIKVCEFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNREFVFKNI
DGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLALHRSYLTGDS
SSGWTAGAAAYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSTF
VEKGIYQTSNFRVQPTESIVRFPNI TNLCPPGEVFNATRFASVYAWNKRKISNCV
ADYSVLVNSASFSTFKCYGVNGTKLNDLCFTNVYADSFVIRGDEVQIAPGQTG
KIADYNYKLDDFTGCVIAWNSNNLDSKVGNYNYLYRLFRKSNLKPFRDIST
EIIYQAGSTPCNGVEGENCYFPLQSYGFQPTNGVGYQPYRVVLSPELLHAPATV
CGPKKSTNLVKNKCVNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVR
DPQTEILDITPCSPGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPT
WRVYSTGSNVFQTRAGCLIGAHEVNNSYECDIPIGAGICASYQTQTNSPGSASSV
ASQSIIAYTMSLGAENSVAYSNNIAIPTNFTISVTTEILPVSMTKTSVDCTMYICG
DSTECNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGG
FNFSQILPDPSPKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF
NGLTVLPPLLDEMIQYTSALLAGTITSGWTFGAGPALQIPFPMQAYRFNGIG
VTQNVLYENQKLIANQFNSAIGKIQDSLSTPSALGKLQDVVNQNAQALNTLVK
QLSSNFGAISSVLNDILSRDPPAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRAS
ANLAATKMECEVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEK
NFTTAPAI CHDGAHFPRGVFVSNGTHWFTQRNFYEQIITTDNTFVSGNCD
VVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVLGDISGINASVVNIQKEI
DRLNEVAKNLNESLIDLQELGKYEQGYIPEAPRDGQAYVRKDGEVLLSTFLG

[0144] It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents.

[0145] Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, compositions, formulations, or methods of use of the invention, may be made without departing from the spirit and scope thereof.

SEQUENCE LISTING

Sequence total quantity: 4
SEQ ID NO: 1 moltype = DNA length = 3714
FEATURE Location/Qualifiers
source 1..3714
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 1
atgttcgtct tctcgtgtgt gctccccctg gttccagcc agtgcgtgaa ctcacaact 60

-continued

cgtaccacgc	tcccaccgcg	ttacaccaac	tcctttacca	ggggcggtga	ttaccagat	120
aagggtgttc	gtagcagcgt	gctgcacagt	acccaggacc	tggtttctcc	tttcttcagc	180
aatgtcacat	gggtttcacgc	catccacgtt	tctggtacta	atggtaccaa	gcgtttcgac	240
aaccccggtc	tcccgtttaa	cgatggtgtc	tacttcgctt	ccaccgaaaa	gtccaacatt	300
atccgtggct	ggatctttgg	caccaccctg	gatagcaaaa	cacagtcact	gctgatttgg	360
aataacgcc	ccaacgtcgt	gataaaagt	tgcaattcc	agttttgcaa	tgatcctttc	420
ctgggagttt	attatcacaa	gaacaacaaa	agttggatgg	aatccgagtt	ccgggtttat	480
tcctctgcaa	ataactgcac	cttcgagtac	gtctctcagc	cttttctcat	ggacctcgaa	540
gggaacaacg	gaaacttcaa	gaatctgagg	gaatttggtt	tcaagaacat	tgacgggtat	600
ttcaagatct	acagcaagca	tacccccatt	aacctcgtga	gggacctgcc	acaaggcttc	660
tcgcctctgg	aaccactcgt	cgacctgcct	ataggcatta	acatcacccg	atttcagacg	720
ctcctggcat	tgacccgaag	ctatctgaca	ccaggtgatt	catcctctgg	ctggacggcc	780
ggtgcgccag	cttattacgt	gggatatctg	cagcctagga	cattcctgct	caagtataat	840
gagaacggca	ctatcactga	tgcatgggac	tgtagccctg	accgctcag	tgagaccaag	900
tgacccctca	agtccttcac	tgttgaaaag	ggtatctatc	aaaccagcaa	ttttagagtc	960
cagcctactg	agagcattgt	agatttctct	aatatcacaa	atctctgtcc	ttttggtgag	1020
gtctttaagt	cgacccgctt	cgccagtggt	tatgcctgga	atcgtaagag	aattagcaac	1080
tggttagcag	actattcagt	ctgtgacaac	tcgcgcagct	tttctacatt	taagtgttac	1140
ggggtgaacg	gcaccaagtt	gaacgatttg	tgcttcacaa	acgtttacgc	cgatagcttt	1200
gttattaggg	gagatgaagt	tcgcccggct	gcccctggcc	aaaccgggaa	aattgaggac	1260
tacaactata	agttgcccga	cgacttcact	ggttggtgta	tcgcctggaa	ctccaacaat	1320
ctggacagta	aggttaggtg	caattataac	tattgtatc	gccttttccg	gaagtccaat	1380
ctgaaacctc	tcgaacggga	catttcaact	gaaatctacc	agggccggaag	tacgccatgt	1440
aacggcggtg	aggggttcaa	ttgttacttc	ccaactgcaa	gctacgggtt	ccagccaact	1500
aatggagttg	gctatcagcc	ttaccgggtg	gtggttcttt	ccttcgagct	tttgcatgct	1560
ccagccacgg	tctgcggacc	aaagaagtca	acaaacttgg	tgaagaacaa	atgcgtaaac	1620
ttcaacttta	acgggtctc	tgccacagga	gtgcttacgg	agtcacaata	gaagtctcct	1680
ccttttcagc	agtttggtcg	agacatcgct	gatacaacgg	atgctgtaag	agacccccag	1740
actttggaga	ttctggacat	taccccatgc	tcatttgccg	gcgtgtcagt	gataccccca	1800
ggtactaaca	cttccaatca	ggttagcggc	ctttaccagg	acgttaattg	taccgaagta	1860
cccgtagcga	tccacgcaga	ccagctgact	cccacttggc	gggtttacag	tacgggttca	1920
aacgttttcc	agacccgtgc	tggtatgcct	atcggtgcgg	agcatgtaaa	caactcatac	1980
gaatgtgaca	tccttatcgg	ggcaggaata	tgcccatctt	accaaacaca	gacaaattct	2040
ccaggctcag	catcttccgt	ggcgtctcag	agtataatcg	catataccat	gagtccttgg	2100
gccgagaatt	cagtcgcgta	ttctacaac	tctatcgcta	tcccaacgaa	cttcacaata	2160
tcgcgcacaa	ccgagattct	ccctgtttct	atgactaaga	ctagtgtgga	ttgtacgatg	2220
tatatctgtg	gggttagcac	aacctgcagt	ttcagtagcg	ctcattttgt		2280
acccaactca	atagagccct	caccggtata	gccgtgggaa	aggataagaa	tactcaagag	2340
gtgtttgccc	aggtgaagca	aatttataaa	actccacct	ttaaggactt	cggtggattt	2400
aattttagtc	agatttctcc	gcacccttcc	aaacctagca	agcggctccc	tattgaggat	2460
ctccttttca	acaaagtgc	cctggccgac	gccgggttca	ttaaacagta	cgggagactgc	2520
ctcggtgaca	tagccgcacg	cgatcttatc	tgtagcacaga	aatttaacgg	tcttaccgct	2580
cttcgcgcac	tggtgacaga	tgaaatgatc	gcccaataca	cctcagcatt	gctggctgggt	2640
accattactt	ctggatggac	atttggtgca	ggacccgctc	tgcatatccc	cttccctatg	2700
cagatggcat	acagattcaa	cgggaattgga	gtcactcaga	atgttctgta	cgagaatcaa	2760
aagttgattg	ccaaccagtt	taactccgca	attggtgaaga	tacaagacag	cctctcttct	2820
actcctcccg	cgttgggaaa	gctgcaggat	gtggtgaatc	agaacgcaca	ggccctgaat	2880
actctggtga	agcagttgag	ctcaaaactt	ggggccatct	cttcgcgtct	caatgacata	2940
ctgagcagac	tcgatccccc	agaggctgag	gtgcagattg	atcgcttgat	cacggggaga	3000
ctccagtcct	tccagacata	tgttaactcag	cagctgatta	gagcggcgga	gatcagagca	3060
tcgcgccacc	ttgcgcgtac	caaaatgtct	gaatgcgtgc	tgggccagtc	caagcggtgt	3120
gatttctgtg	gggaaggata	tcactctgat	tcatttcccc	aatcagctcc	tcacggcgctt	3180
gttttctctg	atgttaacta	cgtgccagct	caggagaaga	atttcaactac	cgcgcctgcc	3240
attttgccatg	acggcaaggc	gcatttcccc	aggggaaggag	tccttgttag	taatgggtaca	3300
caactggtcg	tcacccagcg	taatttctac	gagccacaga	ttattacgac	agacaacact	3360
ttcgatcccg	gtaattgcga	cgtagtcatt	ggcattgtaa	ataataccgt	atacgaccct	3420
ctccagcccg	aacttgacag	ttttaaggaa	gagttggata	aatacttcaa	gaaccatact	3480
ctccagatg	tcgacctggg	tgatatttct	ggaatcaatg	cctctgttgt	taacatttcag	3540
aaagaaatag	atcggtctcaa	tgaggtcgcc	aagaatttga	acgagtcact	gattgacctg	3600
caggagctcg	gaaagtatga	acagggatat	ataccagagg	ccccagaga	tgccagggcc	3660
tatgttcgca	aggacgggga	gtgggtcctg	ctgtccactt	tcctcgata	ataa	3714

SEQ ID NO: 2 moltype = AA length = 1236
FEATURE Location/Qualifiers
source 1..1236
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 2

MFVFLVLLPL	VSSQCVNLTT	RTQLPPAYTN	SFTRGVVYPD	KVFRSSVLHS	TQDLFLPFFS	60
NVTWFHAIHV	SGTNGTKRFD	NPVLPFNDGV	YFASTEKSN	IRGWIFGTTL	DSKTQSLLI	120
NNATNVVIVK	CEPQFCNDPF	LGVIYHKNNK	SWMESEFRVY	SSANNCTFEY	VSQPLFMDLE	180
GKQGNFNKLR	EFVFNKIDGY	FKIYSKHPTI	NLVRDLPQGF	SALEPLVDLP	IGINITRFQT	240
LLALHRSYLT	PGDSSSGWTA	GAAAYVGYL	QPRTFLLKYN	ENGTITDAVD	CALDPLSETK	300
CTLKSFTVEK	GIYQTSNFRV	QPTESIVRFP	NITNLCPFGE	VFNATRFASV	YAWNKRKRISN	360
CVADYSVLVN	SASFSTPKCY	GVNGTKLNDL	CFTNVYADSF	VIRGDEVROI	APGQTKIAD	420
YNYKLPDDFT	GCVIWNSNN	LDSKVGGNYN	YLYRLFRKSN	LKPFERDIST	EIQAGSTPC	480

-continued

NGVEGFNCYF	PLQSYGFQPT	NGVGYQPYRV	VVLSFELLHA	PATVCGPKKS	TNLVKNKCVN	540
FNFNGLTGTG	VLTESNKKFL	PFQQFGRDIA	DTTDAVRDPQ	TLEILDITPC	SFGGVSVITP	600
GTNTSNQVAV	LYQDVNCTEV	PVAIHADQLT	PTWRVYSTGS	NVFQTRAGCL	IGAHEVNNNSY	660
ECDIPIGAGI	CASYQTQINS	PGSASSVASQ	SIAYTMSLG	AENSVAYSNN	SIAIPTNFTI	720
SVTTEILPVS	MTKTSVDCMT	YICGDSSTEC	LLLLQYGSFC	TQLNRALTGI	AVEQDKNTQE	780
VFAQVKQIYK	TPPIKIDGGF	NFSQILPDPS	KPSKRSPIED	LLFNKVTLAD	AGFIKQYGDC	840
LGDIARDLI	CAQKFNGLTV	LPPLLTDEMI	AQYTSALLAG	TITSGWTFGA	GPALQIPFPM	900
QMAYRPNIGI	VTQNVLYENQ	KLIANQFNNSA	IGKIQDSLSS	TPSALGKLQD	VVNQNAQALN	960
TLVKQLSSNF	GAISSVLNDI	LSRLDPPEAE	VQIDRLITGR	LQSLQTYVTQ	QLIRAAEIRA	1020
SANLAATKMS	ECVLGQSKRV	DFCGKGYHLM	SFPQSAPHGV	VFLHVTYVPA	QEKNFTTAPA	1080
ICHDKGAHPF	REGVFSNGT	HWFVTQRNFY	EPQIITDNT	FVSGNCDVVI	GIVNNTVYDP	1140
LQPELDSFKE	ELDKYFKNHT	SPDVLGDIS	GINASVVNIQ	KEIDRLNEVA	KNLNESLIDL	1200
QELGKYEQGY	IPEAPRDGQA	YVRKDGWVL	LSTFLG			1236

SEQ ID NO: 3 moltype = DNA length = 3768
 FEATURE Location/Qualifiers
 source 1..3768
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 3

atggattgga	cgtggatact	tttctctgtt	gctgctgcta	cccgcgta	cagcatgttc	60
gtcttctcgg	tggtgctccc	cctgggtttcc	agccagtgcg	tgaacctcac	aactcgtacc	120
cagctccac	cggcttacac	caactccttt	accaggggcg	tgattatccc	agataaggtg	180
ttctgtagca	gcgtgctgca	cagtacccag	gacctgtttc	tccctttctt	cagcaatgtc	240
acatgggttc	acgccatcca	cgtttctggt	actaatggta	ccaagcgttt	cgacaacccc	300
gtgctcccg	ttaacgatgg	tgcttacttc	gcttccacgg	aaaagtccaa	cattatccgt	360
ggctggatct	ttggcaccac	cctggatagc	aaaacacagt	cactgctgat	tgtgaataac	420
gccaccaacg	tcgtgataaa	agtgtgcgaa	ttccagtttt	gcaatgatcc	tttctggga	480
gtttattatc	acaagaacaa	caaaagttag	atggaatccg	agttccgggt	ttattcctct	540
gcaataaact	gcaccttcga	gtacgtctct	cagccttttc	tcatggacct	cgaagggaaa	600
caaggaaact	tcaagaatct	gagggaaatt	gttttcaaga	acattgacgg	gtatttcaag	660
atctacagca	agcatacccc	cattaacctc	gtgagggaac	tgcacacaag	cttctccgcc	720
ttggaaacc	tcgtcgacct	gcctataggg	attaacatca	cccgatttca	gacgctcctg	780
gcattgcacc	gaagctatct	gacaccaggt	gattcatcct	ctggctggac	ggcgggtgcg	840
gcagcttatt	acgtgggata	tctgcagcct	aggacattcc	tgctcaagta	taatgagaac	900
ggcactatca	ctgatcgagt	ggactgtgcc	cttgaccgcg	tcagtggagc	caagtgcacc	960
ctcaagtcct	tcaactgttg	aaaagggtatc	tatcaaacca	gcaatttttag	agtcacgcct	1020
actgagagca	ttgtcagatt	tcctaatac	acaaatctct	gtccttttgg	tgaggctctt	1080
aatgcgaccc	gcttcgccag	tgtgtatgcc	tggaaatcga	agagaattag	caactgtgta	1140
gcagactatt	cagtcttgta	caactccgcc	agctttttcta	catttaagtg	ttacgggggtg	1200
aacggcacca	agttgaacga	tttgtgcttc	acaaacggtt	acgcccagat	ctttgttatt	1260
aggggagatg	aagttcgcca	gattgcccct	ggccaaaccc	ggaaaattgc	ggactacaac	1320
tataagttgc	ccgacgactt	cactggttgt	gtaatcgcc	ggaactccaa	caatctggac	1380
agtaaggtag	gtggcaatta	taactatttg	tatgccttt	tccggaagtc	caatctgaaa	1440
cccttcgaac	gggacatttc	aactgaaatc	taccaggccg	gaagtacgcc	atgtaacggc	1500
gttgaggggg	tcaattgtta	cttcccactg	caaagctacg	gtttccagcc	aactaatgga	1560
gttggctatc	agccttaccc	gggtggtggt	ctttctctcg	agcttttgca	tgctccagcc	1620
acggtctcgc	gaccaaagaa	gtcaacaaac	ttggtaagaa	acaaatcgct	aaacttcaac	1680
tttaacggtc	tcaactggcc	cagagtgcct	acggagtcca	ataagaagtt	ccttcccttt	1740
cagcagtttg	gtcgagacat	cgctgatata	acggatgctg	taagagaccc	ccagactttg	1800
gagattctcg	acattacccc	atgctcattt	ggcggcgtgt	cagtgtacac	cccaggtaact	1860
aaacacttcca	atcaggttag	ggtcctttac	caggacgtta	attgtaccga	agtaaccgta	1920
gcgatccacg	cagaccagct	gactcccact	tggcgggttt	acagtacggg	ttcaaacggt	1980
ttccagaccc	gtgctggatg	ccttatcggt	gcggagcatg	taaacaaact	atacgaatgt	2040
gacatcccta	tcggggcagg	aatatgcgca	tcttaccaaa	cacagacaaa	ttctccaggg	2100
tcagcatctt	ccgtggcgct	tcagagtata	atcgcatata	ccatgagttc	tggtgccgag	2160
aattcagtcg	cgtattctaa	caattctatc	gctatcccaa	cgaacttcac	aatatccgtc	2220
acaaaccgaga	ttctccctgt	ttctatgact	aagactagtg	tggattgtac	gatgtatatc	2280
tgtggggata	gcacagaatg	cagtaacctg	ctgcttcagt	acggctcatt	ttgtacccaa	2340
ctcaatagag	ccctcaccgg	tatagccgtg	gaacaggata	agaatactca	agagggtgtt	2400
gcccaggtga	agcaaattta	taaaactcca	cctattaagg	acttcgggtg	atttaatttt	2460
agtcagattc	tccccgaccc	ttccaaacct	agcaagcggt	ccctatttga	ggatctcctt	2520
ttcaacaaag	tgaccctggc	cgacgcgggg	ttcatataac	agtacggaga	ctgcctcggt	2580
gacatagccg	cacgcgatct	tatctgtgca	cagaaattta	acggctcttac	cgtccttccg	2640
ccactgttga	cagatgaaat	gatcgcccaa	tacacctcag	cattgctggc	tggtaccatt	2700
acttctggat	ggacatttgg	tgacggaccc	gctctgcaga	tccccttccc	tatgcagatg	2760
gcatacagat	tcaacggaat	tggagtcact	cagaatgttc	tgtacgagaa	tcaaaagttg	2820
attgccaacc	agtttaactc	cgcaatttgt	aagatacaag	acagcctctc	ttctactccc	2880
tccgcgttgg	gaaagctgca	ggatgtggtg	aatcagaacg	cacaggccct	gaatactctg	2940
gtgaagcagt	tgagctcaaa	ctttggggcc	atctcttccg	tcctcaatga	catactgagc	3000
agactcgatc	cccagagggc	tgaggtgcag	attgatcgct	tgatcacggg	gagactccag	3060
tctctccaga	catatgtaac	tcagcagctg	attagagcgg	cggagatcag	agcatccgcc	3120
aaccttgccg	ctacccaaat	gtctgaatgc	gtgctggggc	agtcacagcg	tgtggatttc	3180
tgtgggaagg	gatatcatct	gatgtcattt	ccccaatcag	ctctccacgg	cgttgttttc	3240
ctgcatgtta	actacgtgcc	agctcaggag	aagaatttca	ctacccggcc	tgccatttgc	3300
catgacggca	aggcgcattt	ccccagggaa	ggagctcttg	ttagtaattg	tacacactgg	3360

-continued

ttcgtcacc	agcgtaattt	ctaagagcca	cagattatta	cgacagacaa	cactttcgta	3420
tcggtaatt	gcgacgtagt	cattggcatt	gtaaataata	ccgtatacga	ccctctocag	3480
cccgaaactt	acagttttta	ggaagagttg	gataaatact	tcaagaacca	tacttctcca	3540
gatgtcgacc	tgggtgatat	ttctggaatc	aatgcctctg	ttgttaacat	tcagaaagaa	3600
atagatcggc	tcaatgaggt	cgccaagaat	ttgaacgagt	cactgattga	cctgcaggag	3660
ctcggaaggt	atgaacaggg	atatatacca	gagggcccca	gagatggcca	ggcctatgtt	3720
cgcaaggacg	gggagtggtt	cctgctgtcc	actttctctg	gataataa		3768

SEQ ID NO: 4 moltype = AA length = 1254
 FEATURE Location/Qualifiers
 source 1..1254
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 4

MDWTWILFLV	AAATRVHSMF	VFLVLLPLVS	SQCVNLTRT	QLPPAYTNSF	TRGVYYPDKV	60
FRSSVLHSTQ	DLFLPFFSNV	TWFHAIHVS	TNGTKRFDNP	VLPPNDGVYF	ASTEKSNIIR	120
GWIFGTTLDS	KTQSLIVN	ATNVVIKVE	QFQCNDFPLG	VYYHKNNKSW	MESEFRVYSS	180
ANNCTFEYVS	QPFLMDLEGK	QGNFKNLREF	VFKNIDGYFK	IYSKHTPINL	VRDLPQGFS	240
LEPLVDLP	IGINITRFQTL	LLALHRSYLT	PGDSSSGWTA	GAAYVGYLQ	PRTFLLYNEN	300
GTITDAVDC	ALDPLSEKCT	KLSFTVEKGI	YQTSNFRVQ	PNTESIVRFP	NI	360
NATRFASVYA	WNRKRISNCV	ADYSVLYN	SA	SFSTFKCYGV	NGTKLNDLCF	420
RGDEVQR	IAIPGQTKIAD	YN	YKLPDDFTGC	VIAWNSN	NLD	480
PFERDISTE	I	YQAGSTPCNG	VEGFNCYFPL	QSYGFQPTNG	VGYPYRVVV	540
TVCGPKKSTN	LVKNCVNFN	FNGLTGTGVL	TESNKKFLPF	QQFGRDIADT	TDAVRDPQTL	600
EILDITPCSF	GGSVITPGT	NTSNQVAVLY	QDVNCTEVPV	AIHADQLTPT	WRVYSTGSNV	660
FQTRAGCLIG	AEHVNNSYEC	DIPIGAGICA	SYQTQNSPG	SASSVASQSI	IAYTMSLGAE	720
NSVAYSNN	SI	AIPTNFTISV	TTEILPVSM	T	KTSVDCTMYI	780
LNRLTGI	IAV	EQDKNTQEVF	AQVKIYKTP	PIKDFGGFNF	SQILDPDSKP	840
FNKVT	LDAG	FIKQYGCCLG	DIAARDLICA	QKFNGLTVLP	PLLTDEMIAQ	900
TSGWTFG	AGP	ALQIPFPQM	AYRFNGIGVT	QNVLYENQKL	IANQFNSAIG	960
SALGKLQ	DDVV	NQNAQALNTL	VKQLSSNFGA	ISSVLNDILS	RDPPEAEVQ	1020
SLQTYVT	QQL	IRAAEIRASA	NLAATKMSEC	VLGQSKRVDF	CGKGYHLMSF	1080
LHVTVP	AGE	KNFTTAPAIC	HDGKAHFPRE	GVFVSNGTHW	FVTQRNFYEP	1140
SGNCDDV	VIGI	VNNTVYDPLQ	PELDSFKEEL	DKYFKNHTSP	DVDLGDISGI	1200
IDRLNEVA	KN	LNESLIDLQE	LKYEQGYIP	EAPRDGQAYV	RKDGWVLLS	1254

1. A stabilized spike antigen comprising a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.

2. The stabilized spike antigen of claim 1 operably linked to a leader sequence.

3. The stabilized spike antigen of claim 1 comprising a sequence as set forth in SEQ ID NO:4.

4. A composition comprising a stabilized spike antigen of claim 1.

5. A nucleic acid molecule encoding a stabilized spike antigen of claim 1.

6. The nucleic acid molecule of claim 5 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3.

7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule is incorporated into a nanoparticle.

8. A nanoparticle comprising a nucleic acid molecule encoding a stabilized spike antigen of claim 1.

9. The nanoparticle of claim 8, wherein the nucleic acid molecule encoding the stabilized spike antigen is selected from the group consisting of a DNA molecule and an RNA molecule.

10. An immunogenic composition comprising at least one nucleic acid molecule of claim 5.

11. The immunogenic composition of claim 4, further comprising a pharmaceutically acceptable excipient.

12. The immunogenic composition of claim 4, further comprising an adjuvant.

13. A method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering a stabilized spike antigen of claim 1, or a composition comprising a nucleic acid molecule encoding the same, to the subject.

14. A method of protecting a subject in need thereof from infection with SARS-COV-2, the method comprising administering a stabilized spike antigen of claim 1, or a composition comprising a nucleic acid molecule encoding the same, to the subject, wherein the subject is thereby resistant to one or more SARS-COV-2 strains.

15. A method of treating a subject in need thereof against SARS-COV-2, the method comprising administering a stabilized spike antigen of claim 1, or a composition comprising a nucleic acid molecule encoding the same, to the subject.

16. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises an expression vector.

17. An immunogenic composition comprising at least one nanoparticle of claim 8.

18. The immunogenic composition of claim 10, further comprising a pharmaceutically acceptable excipient.

19. The immunogenic composition of claim 10, further comprising an adjuvant.

20. A method of inducing an immune response against SARS-COV-2 in a subject in need thereof, the method comprising administering an immunogenic composition of claim 17 to the subject.

* * * * *